Vogenx raises $81M in IPO

Vogenx, a metabolic-disease drug developer, raised $81.3 million in its IPO at $13 per share— the high end of its marketed range.

Why it matters: Vogenx is testing how far biotech's IPO window has widened for smaller, modestly financed companies.